Ubiquigent Ltd
Rishi Shah is currently the Head of Chemistry at Ubiquigent Ltd. Prior to this role, Rishi has held various positions at GSK, including Scientific Investigator, Senior Scientist, and Synthetic Medicinal Chemist. Rishi also worked as a Research Scientist at Kuecept Ltd. Rishi's educational background includes a Visiting Scientist degree from Imperial College London, a PhD in Medicinal Chemistry and Chemical Biology from the University of Strathclyde, an MSci in Pharmaceutical Chemistry from Queen Mary University of London, and a Postgraduate Certificate in Professional Development in Medicinal Chemistry from the University of Kent. Additionally, Rishi completed an internship at GSK focused on process chemistry to scale up the anti-cancer drug, Trametinib.
This person is not in any teams
Ubiquigent Ltd
Ubiquigent enables the discovery and development of novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need. Founded 13 years ago, the Company has an unrivalled track record and unique range of specialist services focused on the exploitation of the DUB enzymes and ubiquitin-proteasome system (UPS). As the partner chosen by many leading industry and academic organisations for their drug discovery programmes, Ubiquigent’s experience spans the development of DUB inhibitors and modulators in the fields of protein degradation, stabilisation, and homeostasis. Ubiquigent has an internal pipeline of drug discovery programmes and is developing a strong IP portfolio encompassing DUB inhibitors, DUB-targeting Proteolysis Targeting Chimeras (PROTACs) and DUB-Targeting Chimeras (DUBTACs) for partnering and commercialisation.